MCNEILL JOHN A JR 4

4 · PHARMACEUTICAL PRODUCT DEVELOPMENT INC · Filed Aug 2, 2010

Form 4

Period: 2010-07-30

Director

Transactions

Award
Stock Options (to buy)
2010-07-30+9,090→ 9,090 total
Exercise: $24.26From: 2011-07-30Exp: 2020-07-30→ Common Stock (9,090 underlying)

Holdings

Stock Options (to buy)
Exercise: $13.12From: 2003-05-14Exp: 2013-05-13→ Common Stock (16,561 underlying)
16,561
Common Stock
(indirect: By Partnership)
365,485
Stock Options (to buy)
Exercise: $34.18From: 2006-05-17Exp: 2016-05-16→ Common Stock (4,113 underlying)
4,113
Stock Options (to buy)
Exercise: $19.19From: 2009-05-20Exp: 2019-05-20→ Common Stock (14,053 underlying)
14,053
Stock Options (to buy)
Exercise: $22.98From: 2005-05-18Exp: 2015-05-17→ Common Stock (5,650 underlying)
5,650
Common Stock
(indirect: By Trust)
2,613,942
Stock Options (to buy)
Exercise: $24.52From: 2010-05-20Exp: 2020-05-20→ Common Stock (10,496 underlying)
10,496
Common Stock
78,512
Stock Options (to buy)
Exercise: $12.37From: 2002-05-15Exp: 2012-05-14→ Common Stock (12,421 underlying)
12,421
Common Stock
(indirect: By LLC)
1,195
Stock Options (to buy)
Exercise: $15.28From: 2001-05-15Exp: 2011-05-14→ Common Stock (8,281 underlying)
8,281
Stock Options (to buy)
Exercise: $32.67From: 2007-05-16Exp: 2017-05-15→ Common Stock (6,341 underlying)
6,341
Stock Options (to buy)
Exercise: $41.32From: 2008-05-21Exp: 2018-05-20→ Common Stock (6,485 underlying)
6,485

Footnotes (2)

[F1]The options vest in three equal increments on 7/30/2011, 7/30/2012 and 7/30/2013.
[F2]Exercise price and share amounts reflect an anti-dilution adjustment made in connection with the June 14, 2010 spin-off of Furiex Pharmaceuticals, Inc.

Documents

1 file